The Experts below are selected from a list of 3576 Experts worldwide ranked by ideXlab platform

Hongzhi Tang - One of the best experts on this subject based on the ideXlab platform.

Ratna Sudha Madempudi - One of the best experts on this subject based on the ideXlab platform.

  • Bacillus Coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study
    Probiotics and Antimicrobial Proteins, 2019
    Co-Authors: Ratna Sudha Madempudi, Jayanthi Neelamraju, Jayesh J. Ahire, Sandeep K. Gupta, Vineet K. Shukla
    Abstract:

    Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus Coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects ( n  = 100) diagnosed with functional constipation were supplemented with either B. Coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant ( p  

  • Bacillus Coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study
    Probiotics and Antimicrobial Proteins, 2019
    Co-Authors: Ratna Sudha Madempudi, Jayanthi Neelamraju, Jayesh J. Ahire, Sandeep K. Gupta, Vineet K. Shukla
    Abstract:

    Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus Coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects ( n  = 100) diagnosed with functional constipation were supplemented with either B. Coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant ( p  

  • Antiproliferative Effects of Bacillus Coagulans Unique IS2 in Colon Cancer Cells.
    Nutrition and cancer, 2017
    Co-Authors: Ratna Sudha Madempudi, Arunasree M. Kalle
    Abstract:

    In the present study, the in vitro anticancer (antiproliferative) effects of Bacillus Coagulans Unique IS2 were evaluated on human colon cancer (COLO 205), cervical cancer (HeLa), and chronic myelo...

  • Draft Genome Sequence of the Spore-Forming Probiotic Strain Bacillus Coagulans Unique IS-2.
    Genome announcements, 2016
    Co-Authors: Aditya Upadrasta, Swetha Pitta, Ratna Sudha Madempudi
    Abstract:

    ABSTRACT Bacillus Coagulans Unique IS-2 is a potential spore-forming probiotic that is commercially available on the market. The draft genome sequence presented here provides deep insight into the beneficial features of this strain for its safe use as a probiotic for various human and animal health applications.

Fei Tao - One of the best experts on this subject based on the ideXlab platform.

Ira Schildkraut - One of the best experts on this subject based on the ideXlab platform.

  • A unique restriction endonuclease, Bcgl, from Bacillus Coagulans
    Nucleic acids research, 1993
    Co-Authors: Huimin Kong, Richard D. Morgan, Robert Maunus, Ira Schildkraut
    Abstract:

    We have purified and characterized a new restriction endonuclease, BcgI, which has properties unlike those of the three recognized classes of restriction enzymes. BcgI was isolated from Bacillus Coagulans, and it recognizes the sequence CGAN6TGC. BcgI cleaves double stranded DNA on both strands upstream and downstream of the recognition sequence, so that the recognition sequence is released as a 34-base pair fragment with 2-base 3'-extensions. Mg++ and S-adenosylmethionine are required for cleavage. Sinefungin, a structural analogue of AdoMet which generally inhibits methylase activity, can replace AdoMet in the cleavage reaction. The apparent binding constant (Kappd) for AdoMet is about 100 nM, while the KappD for sinefungin is about 500 nM.

Vineet K. Shukla - One of the best experts on this subject based on the ideXlab platform.

  • Bacillus Coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study
    Probiotics and Antimicrobial Proteins, 2019
    Co-Authors: Ratna Sudha Madempudi, Jayanthi Neelamraju, Jayesh J. Ahire, Sandeep K. Gupta, Vineet K. Shukla
    Abstract:

    Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus Coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects ( n  = 100) diagnosed with functional constipation were supplemented with either B. Coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant ( p  

  • Bacillus Coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study
    Probiotics and Antimicrobial Proteins, 2019
    Co-Authors: Ratna Sudha Madempudi, Jayanthi Neelamraju, Jayesh J. Ahire, Sandeep K. Gupta, Vineet K. Shukla
    Abstract:

    Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus Coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects ( n  = 100) diagnosed with functional constipation were supplemented with either B. Coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant ( p